Skip to content
The Kids Research Institute Australia logo
Donate

Search

$3.4 million funding boost supercharges fight against RSV

National research led by the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, has secured more than $3.4 million to assess the epidemiology of respiratory syncytial virus (RSV) throughout the country and optimise Australia’s immunisation strategy.

Spectacular sunset launch for the Missing Piece Story Books

Wesfarmers Centre of Vaccines and Infectious Diseases researchers Dr Janessa Pickering and Dr August Mikucki travelled to Broome last week for the official launch of the long-awaited Missing Piece story books.

New cultural safety initiative guides best practice for clinical research

Perth investigators involved in a major global trial have launched an innovative Cultural Information Hub to maximise cultural safety for Aboriginal and/or Torres Strait Islander patients participating in research.

Simple SMS ‘nudge’ a powerful prompt for timely vaccination

10,000 families participating in research by The Kids Research Institute Australia have demonstrated the effectiveness of a simple text message for increasing the number of children receiving their vaccinations on time.

COVID-19 risks explained for babies, children and pregnant women

Many parents may be feeling anxious and confused about what COVID-19 means for pregnant women, babies and children.

Whooping cough vaccine could be a new weapon in the fight against food allergies

Researchers from The Kids Research Institute Australia and Curtin University will use a $3.9 million grant from the National Health and Medical Research Council to investigate whether a type of whooping cough vaccine could provide bonus protection against food allergies and eczema.

Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024

In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.

Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery

Subcutaneous delivery of antibiotics is a practical alternative to intravenous administration. Ceftriaxone is commonly used for a variety of infections with limited data on the safety and pharmacokinetics of a 2 g subcutaneous dose. This was a prospective, self-controlled cross-over study in 20 stable inpatients receiving ceftriaxone for their infection. Following an intravenous dose, participants received a single dose of 2 g subcutaneous ceftriaxone, in 50 mL normal saline via gravity feed.

Modelling Micro-Elimination: Third-Trimester Tenofovir Prophylaxis for Perinatal Transmission of Hepatitis B in the Remote Dolpa District of Nepal

Hepatitis B (HBV) prevalence is very high in pregnant women in the Dolpa district of Nepal, a region characterised by a remote geographic landscape and low vaccination coverage. Using mathematical modelling, we evaluated the impact of third-trimester tenofovir disoproxil fumarate (TDF) prophylaxis on HBV burden and estimated the time required to achieve HBV elimination in Dolpa. 

Trends in incident acute rheumatic fever or rheumatic heart disease in Indigenous youth in Western Australia: a retrospective cohort study

To determine age-specific and age-standardised incidence trends of acute rheumatic fever (ARF) or rheumatic heart disease (RHD) among Indigenous Western Australians aged less than 35 years of age.